Premium
Tau positron emission tomographic imaging in aging and early A lzheimer disease
Author(s) -
Johnson Keith A.,
Schultz Aaron,
Betensky Rebecca A.,
Becker J. Alex,
Sepulcre Jorge,
Rentz Dorene,
Mormino Elizabeth,
Chhatwal Jasmeer,
Amariglio Rebecca,
Papp Kate,
Marshall Gad,
Albers Mark,
Mauro Samantha,
Pepin Lesley,
Alverio Jonathan,
Judge Kelly,
Philiossaint Marlie,
Shoup Timothy,
Yokell Daniel,
Dickerson Bradford,
GomezIsla Teresa,
Hyman Bradley,
Vasdev Neil,
Sperling Reisa
Publication year - 2016
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.24546
Subject(s) - tauopathy , neuropathology , positron emission tomography , dementia , pittsburgh compound b , biomarker , neuroscience , medicine , disease , psychology , cognitive impairment , pathology , neurodegeneration , chemistry , biochemistry
Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease‐modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18 F T807 (AV1451), and amyloid‐β PET using 11 C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18 F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18 F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18 F T807 than with mean cortical 11 C PIB. Regional 18 F T807 was correlated with mean cortical 11 C PiB among both impaired and control subjects. Interpretation These findings suggest that 18 F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment. ANN NEUROL 2016;79:110–119